

Investigator Curriculum Vitae

Personal Information

Name: Carmine Liberatore
Title: Dr
Profession: Medical Doctor
Current position: Physician at Clinical Hematology Unit – Santo Spirito Hospital, Pescara

Professional Registrationⁱ

Registration number: 3842
Registration body: OMCEO L'Aquila
Registration expiry date (if applicable): NA
Registration state/province (if applicable): Italy/L'Aquila

Education and Qualificationsⁱⁱ

Institution name	Qualification	Year
EMN Italy	<i>First level master on management of multiple myeloma</i>	2022
University Hospital "Carl Gustav Carus, Dresden (Germany).	<i>Research Fellowship at Hematology and Bone Marrow Transplantation Unit</i>	2020
Vita-Salute San Raffaele University, Milan.	<i>Residency in Hematology</i>	2020
La Sapienza University – Rome	<i>Italian State Examination for Medical Practice</i>	2016
La Sapienza University – Rome	<i>Master's Degree in Medicine and Surgery</i>	2015

Current employment

Institution name: "G. D'Annunzio" University

Investigator Curriculum Vitae

Department: Department of Medicine and Aging Sciences
Institution address: Via Vestina 31, 66100 Chieti
Telephone number: + +39 08713551
E-mail address: carmine.liberatore@asl.pe.it / carmine.liberatore@unich.it

Professional experienceⁱⁱⁱ

Position	Institution name and department	Start year	End year
Research Fellow	Department of Medicine and Aging Sciences , "G. D'Annunzio" University, Chieti	2024	ongoing
Physician Hematologist	Clinical Hematology Unit, Santo Spirito hospital, Pescara	2021	ongoing
Consultant	Lymphoma Unit - Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan	2020	2021

Relevant clinical trial/study experience^{iv}

Investigator Curriculum Vitae

Investigator role	Therapeutic area	Type of trial	Year started	Phase	Ongoing
Principal Investigator	Plasma cell neoplasm C1071032 trial	Interventional Trial	2025	Phase III	Yes
Principal Investigator	Plasma cell neoplasm EMN30 trial	Interventional Trial	2025	Phase III	Yes
Principal Investigator	Plasma cell neoplasm EMN34 trial	Interventional Trial	2024	Phase III	Yes
Sub Investigator	Plasma cell neoplasm Monumental-6 trial	Interventional Trial	2024	Phase III	Yes
Principal Investigator	Plasma cell neoplasm MUST trial	Clinical Study	2024	Other	Yes
Principal Investigator	Plasma cell neoplasm Palladio trial	Clinical Study	2024	Other	Yes
Principal Investigator	Plasma cell neoplasm REALITEC trial	Clinical Study	2024	Other	Yes
Principal Investigator	Plasma cell neoplasm Isa_1q+ trial	Clinical Study	2024	Other	Yes
Principal Investigator	Plasma cell neoplasm TVP-MM trial	Clinical Study	2024	Other	Yes
Principal Investigator	Gaucher Disease EMN29	Interventional Trial	2024	Phase III	Yes
Sub Investigator	Gaucher Disease CHAGAL trial	Clinical Study	2023	Other	No
Sub Investigator	Plasma cell neoplasm DARE-MM trial	Clinical Study	2023	Other	Yes
Sub Investigator	Plasma cell neoplasm C1071006 trial	Interventional Trial	2024	Phase II	Yes
Sub Investigator	Plasma cell neoplasm MARK trial	Interventional Trial	2022	Phase II	Yes
Sub Investigator	Plasma cell neoplasm DarMY PET	Clinical Study	2022	Other	Yes
Sub Investigator	Plasma cell neoplasm KRD real life	Clinical Study	2022	Other	Yes
Sub Investigator	Plasma cell neoplasm EMN 24	Interventional Trial	2022	Phase III	Yes
Sub Investigator	Lymphoproliferative disorders NLG-LBC7 (POLAR BEAR)	Interventional Trial	2021	Phase III	No
Sub Investigator	Lymphoproliferative disorders 2018-523-00US1	Interventional Trial	2021	Phase I	No
Sub Investigator	Lymphoproliferative disorders 2018-689-00US1	Interventional Trial	2021	Phase I	No
Sub Investigator	Lymphoproliferative disorders FIL_RI-CHOP	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders ADCT-402-201	Interventional Trial	2021	Phase II	No

Investigator Curriculum Vitae

Sub Investigator	Lymphoproliferative disorders FIL V-RBAC	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders PCYC-1143-CA	Interventional Trial	2021	Phase III	No
Sub Investigator	Lymphoproliferative disorders TRIANGLE	Interventional Trial	2021	Phase III	No
Sub Investigator	Lymphoproliferative disorders IELSG 44	Clinical Study	2021	Other	No
Sub Investigator	Lymphoproliferative disorders ML41215 URBAN	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders IELSG47	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders CCTL019E2202	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders INCB 50465-203 (Citadel 203)	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders BGB-3111-212:	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders PCYC-1141-CA	Interventional Trial	2021	Phase III	No
Sub Investigator	Lymphoproliferative disorders IELSG39	Interventional Trial	2021	Phase II	No
Sub Investigator	Lymphoproliferative disorders IELSG 37	Interventional Trial	2021	Phase III	No
Sub Investigator	Lymphoproliferative disorders IELSG 37	Interventional Trial	2021	Phase III	No
Sub Investigator	Lymphoproliferative disorders IELSG 40	Clinical Study	2021	Other	No
Sub Investigator	Lymphoproliferative disorders PCI-32765MCL3002 SHINE	Interventional Trial	2021	Phase III	No

Investigator Curriculum Vitae

Training

Research training (including GCP)	Institution name	Year obtained
GCP training R3	TransCelebrate BioPharma	07AUG2025

Date completed^v:

03 JAN 2026



ⁱ As per national legislation

ⁱⁱ Relevant to be an investigator

ⁱⁱⁱ This should cover the preceding 10 years as a maximum

^{iv} Idem

^v The CTR does not require signing individual documents in the clinical trial application – a request for signature could however be subject to national legislation.